Spots Global Cancer Trial Database for lbh589
Every month we try and update this database with for lbh589 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | NCT00445068 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone | NCT00419536 | Hormone Refract... | LBH589 | 18 Years - | Novartis | |
| Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone | NCT00419536 | Hormone Refract... | LBH589 | 18 Years - | Novartis | |
| LBH589 (Panobinostat) for the Treatment of Myelofibrosis | NCT01298934 | Primary Myelofi... Polycythemia Ve... Post-Essential ... | LBH589 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase | NCT00451035 | Chronic Myeloid... | LBH589 | 18 Years - | Novartis | |
| Phase II Trial of LBH589 in Refractory Colorectal Cancer | NCT00690677 | Colorectal Canc... | LBH589 | 18 Years - | Swedish Medical Center | |
| Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | NCT00532389 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone | NCT00493766 | Hormone Refract... | LBH589 | 18 Years - | Novartis | |
| Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | NCT00532675 | Multiple Myelom... | LBH589 Lenalidomide | 18 Years - | Novartis | |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | NCT01433445 | Idiopathic Myel... Post Essential ... Post Polycythem... | panobinostat ruxolitinib | 18 Years - | Novartis | |
| A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | NCT00621244 | Lymphoma Leukemia Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase | NCT00449761 | Leukemia, Myelo... | LBH589 | 18 Years - | Novartis | |
| LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma | NCT00412997 | Tumors Cutaneous T-Cel... | LBH589 | 20 Years - | Novartis | |
| LBH589 and Gemcitabine in the Treatment of Solid Tumors | NCT00550199 | Solid Tumors | LBH589, Gemcita... | 18 Years - | SCRI Development Innovations, LLC | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | NCT01238692 | Diffuse Large B... | LBH589 Rituximab | 18 Years - | Jewish General Hospital | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589 | NCT00472368 | Cancer Patients... | LBH589 | 18 Years - | Novartis | |
| LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | NCT00550277 | Renal Cell Carc... | LBH589 | 18 Years - | SCRI Development Innovations, LLC | |
| Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | NCT02204553 | Multiple Myelom... | Panobinostat | 18 Years - | Novartis | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589 and Gemcitabine in the Treatment of Solid Tumors | NCT00550199 | Solid Tumors | LBH589, Gemcita... | 18 Years - | SCRI Development Innovations, LLC | |
| Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | NCT00978432 | Diffuse Large B... | RAD001 LBH589 Doublet (RAD001... | 18 Years - | Duke University | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | NCT00621244 | Lymphoma Leukemia Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Trial of LBH589 in Metastatic Thyroid Cancer | NCT01013597 | Thyroid Carcino... | LBH589 | 18 Years - | University of Wisconsin, Madison | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | NCT00691938 | Leukemia, Myelo... Myelodysplastic... | LBH589 Decitabine | 60 Years - | Washington University School of Medicine | |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | NCT01613976 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | Panobinostat | 20 Years - | Novartis | |
| Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | NCT01032148 | Hodgkin's Lymph... Non-Hodgkin's L... | LBH589 | 18 Years - | Roswell Park Cancer Institute | |
| Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) | NCT01090973 | Non-Hodgkin's L... | LBH589 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | NCT00699296 | Cutaneous T-Cel... Leukemia-Lympho... | Panobinostat (L... | 20 Years - | Novartis | |
| Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | NCT00699296 | Cutaneous T-Cel... Leukemia-Lympho... | Panobinostat (L... | 20 Years - | Novartis | |
| Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | NCT00535951 | Carcinoma, Non-... Mesothelioma | LBH589 | 18 Years - | Novartis | |
| A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors | NCT00503451 | Non-Hodgkin Lym... Neoplasms | LBH589 | 18 Years - | Novartis | |
| CINC424A2X01B Rollover Protocol | NCT02386800 | Primary Myelofi... Polycythemia Ve... Graft Versus Ho... Acute Myeloid L... Thalassemia | ruxolitinib panobinostat | 1 Month - | Novartis | |
| Panobinostat (LBH589) in Patients With Metastatic Melanoma | NCT01065467 | Melanoma Malignant Melan... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase | NCT00449761 | Leukemia, Myelo... | LBH589 | 18 Years - | Novartis | |
| LBH589 (Panobinostat) for the Treatment of Myelofibrosis | NCT01298934 | Primary Myelofi... Polycythemia Ve... Post-Essential ... | LBH589 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase | NCT00451035 | Chronic Myeloid... | LBH589 | 18 Years - | Novartis | |
| LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | NCT00691938 | Leukemia, Myelo... Myelodysplastic... | LBH589 Decitabine | 60 Years - | Washington University School of Medicine | |
| Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | NCT00532389 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | NCT00567879 | Breast Cancer | Panobinostat Trastuzumab | 18 Years - | Novartis | |
| LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | NCT00632489 | Breast Cancer | LBH589 Capecitabine Lapatinib | 18 Years - | SCRI Development Innovations, LLC | |
| Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | NCT00532675 | Multiple Myelom... | LBH589 Lenalidomide | 18 Years - | Novartis | |
| Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma | NCT00967044 | Lymphoma | Panobinostat Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | NCT00632489 | Breast Cancer | LBH589 Capecitabine Lapatinib | 18 Years - | SCRI Development Innovations, LLC | |
| Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT00939159 | Myelodysplastic... | LBH589 | 18 Years - | M.D. Anderson Cancer Center | |
| A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | NCT00788931 | HER-2 Positive ... Metastatic Brea... | IV LBH589 Oral LBH589 trastuzumab paclitaxel | 18 Years - | Novartis | |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | NCT01238692 | Diffuse Large B... | LBH589 Rituximab | 18 Years - | Jewish General Hospital | |
| LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | NCT00632489 | Breast Cancer | LBH589 Capecitabine Lapatinib | 18 Years - | SCRI Development Innovations, LLC | |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Panobinostat (LBH589) in Patients With Metastatic Melanoma | NCT01065467 | Melanoma Malignant Melan... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors | NCT00556088 | Solid Tumors | LBH589, Paclita... | 18 Years - | SCRI Development Innovations, LLC | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
